(Article 223-16 of the General Regulations of the Autorité des Marchés Financiers)
Market : NYSE Euronext Paris ISIN Code: FR 0010417345
| Date | Total number of shares | Total number of voting rights |
| 09/30/2024 | 96,501,526 | Total gross of voting rights: 96,501,526 |
| Total net* of voting rights: 96,199,467 |
* Net total = total number of voting rights attached to shares – shares without voting rights
| Last Trade: | US$12.91 |
| Daily Volume: | 0 |
| Market Cap: | US$463.930M |
November 11, 2025 October 28, 2025 October 06, 2025 | |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
